- In November 2021, Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in therapies for central nervous system disorders and rare diseases, announced that the U.S. Food and Drug Administration (FDA) had accepted its Investigational New Drug (IND) application for SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) to treat spinocerebellar ataxia (SCA). Additionally, the FDA granted the program Fast Track designation for SCA in the U.S. SLS-005 has also received Orphan Drug designation for spinocerebellar ataxia type 3 (SCA3) from both the FDA and the European Medicines Agency (EMA) in the EU
